Paving the way for immunotherapy in pancreatic cancer by unravelling its tumour microenvironment and exploring a novel combination immunotherapy consisting of a CD40 agonist and interleukin-15 University of Antwerp
Pancreatic Ductal Adenocarcinoma (PDAC) has the worst 5-year survival of all cancers nowadays and is projected to become the 2nd leading cause of cancer-related death by the end of this decade. Despite hopeful breakthroughs in new treatment options for other cancer types, no improvement has been made for pancreatic cancer patients. The unique tumour microenvironment (TME) of PDAC is held responsible for the great amount of therapy resistance ...